Jeff Yass’s Apexigen, Inc. Common Stock APGN Stock Holding History

Jeff Yass’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,546	Closed	-$7.77K	–	13575
2023 Q1	$7.77K	Buy	15,546 +3,695	+31%	+$4.45K	﹤0.01%	12241
2022 Q4	$8.18K	Buy	+11,851	New	+$23.1K	﹤0.01%	11970
2022 Q3	–	Sell	-113,358	Closed	-$922K	–	14472
2022 Q2	$1.15M	Buy	113,358 +95,404	+531%	+$966K	﹤0.01%	6176
2022 Q1	$181K	Buy	+17,954	New	+$180K	﹤0.01%	11362
2021 Q4	–	Sell	-11,587	Closed	-$115K	–	14195
2021 Q3	$115K	Buy	+11,587	New	+$115K	﹤0.01%	11975

Other funds holding APGN

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Yu Fan $108M AUM 137.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jeff Yass's APGN Position: Q2 2023 in Review

Jeff Yass sold out of Apexigen, Inc. Common Stock (APGN) in Q2 2023, closing a stake of 15,546 shares — an estimated $7.77K sold.

Jeff Yass first reported a position in APGN in Q3 2021 and held it in 5 quarters. The position peaked at $1.15M in Q2 2022. 17 funds tracked by Wall St. Rank hold APGN as of Q2 2023.

Jeff Yass reported no remaining Apexigen, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jeff Yass sold 15,546 Apexigen, Inc. Common Stock shares in Q2 2023, an estimated $7.77K.
Jeff Yass first reported a position in Apexigen, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
Jeff Yass's Apexigen, Inc. Common Stock position peaked at $1.15M in Q2 2022.
17 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.